Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738261 | 0.87 | PRCP (0.83) | PRCPMEN1GAA | |
| SCHEMBL3865487 | 0.84 | PRCP (0.97) | PRCPMEN1GAA | |
| SCHEMBL28083503 | 0.84 | PRCP (0.90) | PRCPMEN1GAA | |
| SCHEMBL31374586 | 0.83 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL9600234 | 0.83 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL31374588 | 0.83 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL2795999 | 0.82 | PRCP (1.00) | PRCPMEN1GAA | |
| SCHEMBL1011373 | 0.82 | PRCP (1.00) | PRCPMEN1GAA | |
| SCHEMBL29768302 | 0.82 | PRCP (1.00) | PRCPMEN1GAA | |
| SCHEMBL2793867 | 0.82 | PRCP (1.00) | PRCPMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021140-A1 | COMPOUND FOR DEGRADING TARGET PROTEIN | 海南先声再明医药股份有限公司 | 2025-01-30 | — | — | WO | disclosed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| EP-2406217-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103001-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2010-09-16 | — | — | WO | disclosed |
| EP-1000621-A2 | Use of 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz (CD) indoles for treating motion sickness and vomiting | ELI LILLY AND COMPANY (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0506363-B1 | 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles | LILLY CO ELI (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0506369-B1 | 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[CD]indoles | LILLY CO ELI (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5783590-A | ADJUSTMENT OF SEROTONIN CONCENTRATION IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-07-21 | — | — | US | disclosed |
| US-5750554-A | COMPOUNDS FOR TREATMENT OF ANXIETY, DEPRESSION, ANTISECRETORY AGENTS, HYPOTENSIVE AGENTS AND TREATMENT OF EATING PROBLEMS | ELI LILLY AND COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5364856-A | Modification of serotonin function | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5347013-A | FOR TREATING MAMMALS WITH SEROTONIN RELATED DISORDERS | ELI LILLY AND COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0590970-A1 | 6-Heterocyclyl-4-amino-1,2,2a,3,4,5-hexahydrobenz CD indoles for treating motion sickness and vomiting | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0590971-A1 | 6-Heterocyclyl-4-amino-1,3,4,5-tetrahydrobenz CD indoles for treating motion sickness and vomiting | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5244912-A | Serotonin antagonist | ELI LILLY AND COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5244911-A | Serotonin antagonist | ELI LILLY AND COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0506363-A1 | 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506369-A1 | 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[CD]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4309345-A | POTASSIUM-SPARING DIURETICS | CIBA-GEIGY CORPORATION (US) | 1982-01-05 | — | — | US | disclosed |
| US-4173633-A | DIURETICS | CIBA-GEIGY CORPORATION (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR3C, TPH2 | PRCP 1603/4885CHRNB2 1646/4885CHRNB4 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.